These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38522775)
21. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1. Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276 [TBL] [Abstract][Full Text] [Related]
22. Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model. Ren X; Corrigan DT; Zang X STAR Protoc; 2022 Dec; 3(4):101818. PubMed ID: 36386885 [TBL] [Abstract][Full Text] [Related]
23. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells. Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance. Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868 [TBL] [Abstract][Full Text] [Related]
25. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma. Liao X; Zhang D Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443 [TBL] [Abstract][Full Text] [Related]
26. Expression of HHLA2, TMIGD2, and GITR in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma. Zhang MJ; Wang S; Wu CC; Wu L; Sun ZJ J Oral Pathol Med; 2022 Apr; 51(4):379-387. PubMed ID: 35226778 [TBL] [Abstract][Full Text] [Related]
27. Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases. Achinko DA; Dormer A; Narayanan M; Norman EF BMC Immunol; 2021 Jul; 22(1):49. PubMed ID: 34320928 [TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma. Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C Nephron; 2019; 141(4):256-264. PubMed ID: 30602154 [TBL] [Abstract][Full Text] [Related]
29. Potential Therapeutic Targets of B7 Family in Colorectal Cancer. Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R Front Immunol; 2020; 11():681. PubMed ID: 32477326 [TBL] [Abstract][Full Text] [Related]
30. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro. Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536 [TBL] [Abstract][Full Text] [Related]
31. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. Janakiram M; Chinai JM; Zhao A; Sparano JA; Zang X Oncoimmunology; 2015 Aug; 4(8):e1026534. PubMed ID: 26405587 [TBL] [Abstract][Full Text] [Related]
32. Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. Luo M; Lin Y; Liang R; Li Y; Ge L J Inflamm Res; 2021; 14():4217-4228. PubMed ID: 34483677 [TBL] [Abstract][Full Text] [Related]
33. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis. Shimonosono M; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Uenosono Y; Ishigami S; Natsugoe S Oncotarget; 2018 Apr; 9(31):22069-22078. PubMed ID: 29774123 [TBL] [Abstract][Full Text] [Related]
34. Comparison of mismatch repair and immune checkpoint protein profile with histopathological parameters in pancreatic, periampullary/ampullary, and choledochal adenocarcinomas. Aydın AH; Turhan N World J Gastrointest Oncol; 2024 Mar; 16(3):875-882. PubMed ID: 38577456 [TBL] [Abstract][Full Text] [Related]
35. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer. Wei L; Tang L; Chang H; Huo S; Li Y Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567 [TBL] [Abstract][Full Text] [Related]
36. The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma. Byun JM; Cho HJ; Park HY; Lee DS; Choi IH; Kim YN; Jeong CH; Kim DH; Hwa Im D; Min BJ; Lee KB; Sung MS; Jeong DH Medicine (Baltimore); 2021 Jan; 100(1):e23691. PubMed ID: 33429737 [TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis. Wang B; Ran Z; Liu M; Ou Y Front Immunol; 2019; 10():1573. PubMed ID: 31379814 [TBL] [Abstract][Full Text] [Related]
38. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma. Long L; Zhang L; Yang Y; Zhou Y; Chen H Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955 [No Abstract] [Full Text] [Related]
39. Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma. Nishihara D; Kijima T; Arai K; Kamai T Int Urol Nephrol; 2023 Apr; 55(4):867-874. PubMed ID: 36598731 [TBL] [Abstract][Full Text] [Related]
40. HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells. Guo H; Zhang C; Tang X; Zhang T; Liu Y; Yu H; Li Y; Wang R Inflammation; 2022 Aug; 45(4):1585-1599. PubMed ID: 35175496 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]